ANGPTL4 Variant (E40K)

A single inherited change in one gene can give you a measurable head start on heart disease and diabetes for life. Carrying one copy of this particular change lowers triglycerides by roughly 13 to 20 percent, nudges HDL cholesterol higher, and is linked to a meaningfully lower lifetime risk of heart attack and type 2 diabetes.

This test tells you whether you are one of the roughly 2 to 3 percent of people of European ancestry who carry this protective change. It is information you cannot get from a standard lipid panel, and once you know it, your result does not change.

What This Variant Actually Does

ANGPTL4 (angiopoietin-like protein 4) is a protein your body uses to slow down how quickly fat gets pulled out of your bloodstream. It works by blocking an enzyme called LPL (lipoprotein lipase), which is the enzyme that grabs triglycerides out of circulating blood and moves them into tissues. When ANGPTL4 is fully active, LPL is more blocked, and triglycerides stay higher in the blood.

The E40K variant changes a single building block of the ANGPTL4 protein, making the protein fall apart faster after it leaves the cell. Less stable ANGPTL4 means less braking on LPL, which means triglycerides get cleared more efficiently. Carriers essentially have a more efficient fat-clearing system from birth.

Heart Disease Risk

The most consistent finding about the E40K variant is its effect on coronary artery disease, the kind of arterial damage that leads to heart attacks. In a study of 42,930 people from the DiscovEHR health system cohort, carriers had about 19 percent lower odds of coronary artery disease compared with non-carriers (odds ratio 0.81).

In the long-running Atherosclerosis Risk in Communities study, which tracked about 10,000 adults over roughly 15 years, carriers had about 39 percent lower risk of new coronary heart disease (hazard ratio 0.61) after adjusting for major risk factors like blood pressure, smoking, and BMI (body mass index). A 2024 phenome-wide analysis in Finnish adults confirmed the pattern, finding carriers had lower odds of coronary artery disease.

When researchers in that Finnish dataset looked across more than a thousand different disease endpoints, they found no condition where the variant raised risk. The protection appears to come without a meaningful trade-off.

Type 2 Diabetes

Carrying this variant also lowers your odds of developing type 2 diabetes. A combined analysis of more than 80,000 diabetes cases and nearly half a million controls found carriers had lower odds of type 2 diabetes (odds ratio approximately 0.89). After accounting for body mass index, the protection was slightly stronger. Carriers also tend to have lower fasting blood sugar and better insulin sensitivity.

Reconciling Earlier Conflicting Reports

If you read older write-ups, you may see claims that this variant might actually raise cardiovascular risk despite improving lipid numbers. That picture has been decisively reversed. Studies with tens of thousands to hundreds of thousands of participants now consistently show the variant lowers heart disease risk. The earlier disagreement came from underpowered cohorts producing noisy results, not a real biological signal pointing the other way.

How Results Are Reported

This is a genetic test that returns one of three possible results based on your two copies of the ANGPTL4 gene. The numbers below come from large European-ancestry populations and frequencies vary by ancestry. Compare your result with the published carrier patterns to know where you sit.

Carrier frequency varies meaningfully by ancestry. The variant has been documented in higher proportions in some populations such as Tunisian cohorts and is very rare in people of African ancestry. Your lab may report your result using slightly different naming, but the underlying genotype categories are the same.

What This Result Cannot Tell You

Knowing your status is a snapshot of one specific piece of your cardiovascular wiring. It does not capture your LDL cholesterol, your ApoB (apolipoprotein B, a measure of how many cholesterol-carrying particles are in your blood), your Lp(a) (lipoprotein little a, an inherited particle that drives heart attack risk independently of cholesterol), your blood pressure, your inflammation, or your blood sugar. Carriers can still develop heart disease if their other risk factors are bad enough. Non-carriers can still have excellent cardiovascular health.

Tracking What Matters Around This Result

Because this is a genetic test, the result itself never changes. You take it once. What does change, and what deserves regular tracking, are the lipid and metabolic markers your variant influences. If you are a carrier, your triglycerides and HDL should already look favorable, but you still want to monitor LDL, ApoB, fasting glucose, and HbA1c (hemoglobin A1c, a three-month average of your blood sugar) at least annually so you can catch any drift early.

If you are not a carrier, the absence of this protective variant does not mean you are at high risk. It just means you do not have this particular tailwind. Your trajectory is determined by everything else: standard lipids, ApoB, blood pressure, weight, glucose handling, and lifestyle. Those numbers are what to track every six to twelve months.

What to Do With This Information

There is no abnormal result here in the usual sense. You are either a carrier or you are not. What matters is how this information fits into your broader cardiovascular workup. If you carry the variant but still have high triglycerides, high ApoB, or other red flags, that combination tells you the protective genetics are not enough to overcome whatever else is happening. That pattern deserves a comprehensive lipid panel, ApoB, Lp(a), and a metabolic workup, ideally with a preventive cardiologist if your risk picture is complex.

If you are a non-carrier with already-good lipids, you do not need to do anything different. If you are a non-carrier with borderline numbers, the absence of this variant is one more reason to act early on the modifiable risk factors you do have.

When Results Can Be Misleading

• Variant-specific testing limits: this test looks for the E40K change specifically. If you have a different rare loss-of-function change in the same gene, this test will not detect it. A non-carrier result rules out E40K, not all protective ANGPTL4 variants.
• Sample mix-ups: because the result is binary and lifelong, a wrong answer is consequential. If your result conflicts with a strong family history pattern, it is reasonable to repeat the test on a fresh sample.
• Ancestry-specific frequency: if your ancestry is from a population where this variant is very rare, a non-carrier result is statistically expected and tells you less than it would in a population where the variant is more common.